Opinion

Video

Advancing Pharmacist Engagement in Biliary Tract Cancer: Disease State and Treatment Considerations

Author(s):

Courtney Cavalieri, PharmD, BCOP,Kenneth Tham, PharmD, BCOP
Medcast|Medcast Podcasts

Courtney Cavalieri, PharmD, BCOP, and Kenneth Tham, PharmD, BCOP, discuss how pharmacists play a crucial role in managing biliary tract cancer patients by providing expertise on biomarker testing, treatment selection between targeted therapies like FGFR and HER2 inhibitors, developing monitoring protocols for unique toxicities such as hyperphosphatemia, and educating patients on side effect management to optimize treatment outcomes in this rare cancer type.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
1 expert in this video
1 expert in this video
5 experts in this video
1 expert is featured in this series.
5 experts in this video
5 experts in this video
1 expert is featured in this series.
1 expert is featured in this series.
5 experts in this video
5 experts in this video
Related Content
Neuron cells, brain activity -- Image credit: Matthieu | stock.adobe.com
March 4th 2024

Integration of DBS Shows Promise Identifying Dysfunctional Brain Circuits, Treating Brain Disorders

Gillian McGovern, Associate Editor
Protecting Against Shingles: Discussing With Your Patients Why Vaccination Matters
October 4th 2024

Protecting Against Shingles: Discussing With Your Patients Why Vaccination Matters

Trisha Winroth, PharmD Ashly McPhillips, PharmD
3d illustration of human body organ -- Image credit: PIC4U | stock.adobe.com
January 22nd 2024

Study Findings Suggest Liver Creates Palmitic Acid, Maintaining Brain Health

Gillian McGovern, Associate Editor
Protecting Against Shingles: Discussing With Your Patients Why Vaccination Matters
October 4th 2024

Protecting Against Shingles: Discussing With Your Patients Why Vaccination Matters

Trisha Winroth, PharmD Ashly McPhillips, PharmD
FDA Accepts sBLA for Tisotumab Vedotin-tftv for the Treatment of Recurrent, Metastatic Cervical Cancer
January 9th 2024

FDA Accepts sBLA for Tisotumab Vedotin-tftv for the Treatment of Recurrent, Metastatic Cervical Cancer

Gillian McGovern, Associate Editor
Image credit: Dglimages | stock.adobe.com
January 9th 2024

Study Data Show Telemedicine Endocrinology Care Not as Effective as In-Person Care

Erin Hunter, Associate Editor